Clinical Review

Update on Management of Barrett’s Esophagus for Primary Care Providers

Journal of Clinical Outcomes Management. 2018 March;25(3)

References

1. Shaheen NJ, Falk GW, Iyer PG, Gerson LB; American College of Gastroenterology. ACG Clinical Guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol 2016;111:30–50; quiz 51.

2. Peters JH, Clark GW, Ireland AP. Outcome of adenocarcinoma arising in Barrett’s esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg 1994;108:813–21; discussion 821–2.

3. Streitz JM Jr, Andrews CW Jr, Ellis FH Jr. Endoscopic surveillance of Barrett’s esophagus. Does it help? J Thorac Cardiovasc Surg 1993;105:383–7; discussion 387–8.

4. Spechler SJ, Souza RF. Barrett’s esophagus. N Engl J Med 2014;371:836–45.

5. Spechler SJ, Sharma P, Souza RF, et al; American Gastroenterological Association. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology 2011;140:1084–91.

6. Sharma P, McQuaid K, Dent J, et al; AGA Chicago Workshop. A critical review of the diagnosis and management of Barrett’s esophagus: the AGA Chicago Workshop. Gastroenterology 2004;127:310–30.

7. ASGE Standards of Practice Committee, Evans JA, Early DS; Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy. The role of endoscopy in Barrett’s esophagus and other premalignant conditions of the esophagus. Gastrointest Endosc 2012;76(6):1087–94.

8. Wani S, Rubenstein JH, Vieth M, Bergman J. Diagnosis and management of low–grade dysplasia in Barrett’s esophagus: Expert review from the clinical practice updates Committee of the American Gastroenterological Association. Gastroenterology 2016;151:822–835.

9. American Gastroenterological, A., et al., American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology, 2011. 140(3): p. 1084–91. [Same as #5]

10. Van Eyken P. Definition of Barrett’s oesophagus. Acta Gastroenterol Belg 2000;63:10–2.

11. Hirota WK, Loughney TM, Lazas DJ, et al. Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data. Gastroenterology 1999;116(2):277–85.

12. Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA. Prevalence of columnar–lined (Barrett’s) esophagus. Comparison of population–based clinical and autopsy findings. Gastroenterology 1990;99:918–22.

13. Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett’s esophagus in asymptomatic individuals. Gastroenterology 2002;123:461–7.

14. Van der Veen AH, Dees J, Blankensteijn JD, Van Blankenstein M. Adenocarcinoma in Barrett’s oesophagus: an overrated risk. Gut 1989;30:14–8.

15. Winters C Jr, Spurling TJ, Chobanian SJ, et al. Barrett’s esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987;92:118–24.

16. Wani S, Falk G, Hall M, et al. Patients with nondysplastic Barrett’s esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2011;9:220–7;quiz e26.

17. Ward EM, Wolfsen HC, Achem SR, et al. Barrett’s esophagus is common in older men and women undergoing screening colonoscopy regardless of reflux symptoms. Am J Gastroenterol 2006;101:12–7.

18. Rex DK, Cummings OW, Shaw M. Screening for Barrett’s esophagus in colonoscopy patients with and without heartburn. Gastroenterology 2003;125:1670–7.

19. Rubenstein JH, Taylor JB. Meta–analysis: the association of oesophageal adenocarcinoma with symptoms of gastro–oesophageal reflux. Aliment Pharmacol Ther 2010;32:1222–7.

20. Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825–31.

21. Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett’s esophagus in the general population: an endoscopic study. Gastroenterology, 2005;129:1825–31.

22. Sampliner RE. A population prevalence of Barrett’s esophagus––finally. Gastroenterology 2005; 129:2101–3.

23. Abrams JA, Fields S, Lightdale CJ, Neugut AI. Racial and ethnic disparities in the prevalence of Barrett’s esophagus among patients who undergo upper endoscopy. Clin Gastroenterol Hepatol 2008;6:30–4.

24. Corley DA, Kubo A, Levin TR, et al. Race, ethnicity, sex and temporal differences in Barrett’s oesophagus diagnosis: a large community–based study, 1994–2006. Gut 2009;58:182–8.

25. Kamat P, Wen S, Morris J, Anandasabapathy S. Exploring the association between elevated body mass index and Barrett’s esophagus: a systematic review and meta–analysis. Ann Thorac Surg 2009;87:655–62.

26. Jacobson BC, Chan AT, Giovannucci EL, Fuchs CS. Body mass index and Barrett’s oesophagus in women. Gut 2009;58:1460–6.

27. Orloff M, Peterson C, He X, et al. Germline mutations in MSR1, ASCC1, and CTHRC1 in patients with Barrett esophagus and esophageal adenocarcinoma. JAMA 2011;306:410–9.

28. Sharma N, Ho KY. Risk Factors for Barrett’s oesophagus. Gastrointest Tumors 2016;3:103–8.

29. Spechler SJ. Barrett’s esophagus. Semin Gastrointest Dis 1996;7:51–60.

30. Ronkainen J, Talley NJ, Storskrubb T. Erosive esophagitis is a risk factor for Barrett’s esophagus: a community–based endoscopic follow–up study. Am J Gastroenterol 2011;106:1946–52.

31. Kim SL, Wo JM, Hunter JG. The prevalence of intestinal metaplasia in patients with and without peptic strictures. Am J Gastroenterol 1998;93:53–5.

32. Spechler SJ. Clinical practice. Barrett’s esophagus. N Engl J Med 2002;346:836–42.

33. Riddell RH, Odze RD. Definition of Barrett’s esophagus: time for a rethink––is intestinal metaplasia dead? Am J Gastroenterol 2009;104:2588–94.

34. Sharma P, Morales TG, Sampliner RE. Short segment Barrett’s esophagus––the need for standardization of the definition and of endoscopic criteria. Am J Gastroenterol 1998;93:1033–6.

35. Eloubeidi MA, Provenzale D. Does this patient have Barrett’s esophagus? The utility of predicting Barrett’s esophagus at the index endoscopy. Am J Gastroenterol 1999;94:937–43.

36. Rudolph RE, Vaughan TL, Storer BE, et al. Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med 2000;132:612–20.

37. Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett’s esophagus: the Prague C & M criteria. Gastroenterology 2006;131:1392–9.

38. Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett’s esophagus patients: results from a large population–based study. J Natl Cancer Inst 2011;103:1049–57.

39. Shaheen NJ, Dulai GS, Ascher B, et al. Effect of a new diagnosis of Barrett’s esophagus on insurance status. Am J Gastroenterol 2005;100:577–80.

40. Canto MI, Setrakian S, Willis J, et al. Methylene blue–directed biopsies improve detection of intestinal metaplasia and dysplasia in Barrett’s esophagus. Gastrointest Endosc 2000;51:560–8.

41. Scotiniotis IA, Kochman ML, Lewis JD. Accuracy of EUS in the evaluation of Barrett’s esophagus and high–grade dysplasia or intramucosal carcinoma. Gastrointest Endosc 2001;54:689–96.

42. Kobayashi K, Izatt JA, Kulkarni MD, et al. High–resolution cross–sectional imaging of the gastrointestinal tract using optical coherence tomography: preliminary results. Gastrointest Endosc 1998;47:515–23.

43. Georgakoudi I, Jacobson BC, Van Dam J, et al. Fluorescence, reflectance, and light–scattering spectroscopy for evaluating dysplasia in patients with Barrett’s esophagus. Gastroenterology 2001. 120: 1620–9.

44. Wallace MB, Sharma P, Lightdale C, et al. Preliminary accuracy and interobserver agreement for the detection of intraepithelial neoplasia in Barrett’s esophagus with probe–based confocal laser endomicroscopy. Gastrointest Endosc 2010;72:19–24.

45. Qumseya BJ, Wang H, Badie N, et al. Advanced imaging technologies increase detection of dysplasia and neoplasia in patients with Barrett’s esophagus: a meta–analysis and systematic review. Clin Gastroenterol Hepatol 2013;11:1562–70.e1–2.–

46. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1999;94:1434–42.

47. Inadomi JM, Sampliner R, Lagergren J. Screening and surveillance for Barrett esophagus in high–risk groups: a cost–utility analysis. Ann Intern Med 2003;138:176–86.

48. Conio M, Blanchi S, Lapertosa G, et al. Long–term endoscopic surveillance of patients with Barrett’s esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study. Am J Gastroenterol 2003;98:1931–9.

49. Rastogi A, Puli S, El–Serag HB, et al. Incidence of esophageal adenocarcinoma in patients with Barrett’s esophagus and high–grade dysplasia: a meta–analysis. Gastrointest Endosc 2008;67:394–8.

50. Kadri SR, Lao–Sirieix P, O’Donovan M, et al. Acceptability and accuracy of a non–endoscopic screening test for Barrett’s oesophagus in primary care: cohort study. BMJ 2010;341:c4372.

51. Sharma, P., et al., A critical review of the diagnosis and management of Barrett’s esophagus: the AGA Chicago Workshop. Gastroenterology, 2004. 127(1): p. 310–30. [Same as #6]

52. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2013;108:308–28; quiz 329.

53. Kim SL, Waring JP, Spechler SJ, et al. Diagnostic inconsistencies in Barrett’s esophagus. Department of Veterans Affairs Gastroesophageal Reflux Study Group. Gastroenterology 1994;107:945–9.

54. Kastelein F, Spaander MC, Steyerberg EW, et al; ProBar Study Group. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett’s esophagus. Clin Gastroenterol Hepatol 2013;11:382–8.

55. El–Serag HB, Aguirre TV, Davis S, et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett’s esophagus. Am J Gastroenterol 2004;99:1877–83.

56. Nguyen DM, El–Serag HB, Henderson L, et al. Medication usage and the risk of neoplasia in patients with Barrett’s esophagus. Clin Gastroenterol Hepatol 2009;7:1299–304.

57. Singh S, Garg SK, Singh PP, et al. Acid–suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett’s oesophagus: a systematic review and meta–analysis. Gut 2014;63:1229–37.

58. Spechler SJ, Lee E, Ahnen D, et al. Long–term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow–up of a randomized controlled trial. JAMA 2001;285:2331–8.

59. Peters FT, Ganesh S, Kuipers EJ, et al. Endoscopic regression of Barrett’s oesophagus during omeprazole treatment; a randomised double blind study. Gut 1999;45:489–94.

60. Ouatu–Lascar R, Triadafilopoulos G. –Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett’s esophagus. Am J Gastroenterol 1998;93:711–6.

61. Maret–Ouda J, Konings P, Lagergren J, Brusselaers N. Antireflux surgery and risk of esophageal adenocarcinoma: A systematic review and meta–analysis. Ann Surg 2016;263:251–7.

62. Evans, J.A., et al., The role of endoscopy in Barrett’s esophagus and other premalignant conditions of the esophagus. Gastrointest Endosc, 2012. 76(6): p. 1087–94. [Same as #7]

63. ASGE Standards of Practice Committee, Evans JA, Early DS,et al; American Society for Gastrointestinal Endoscopy. The role of endoscopy in the assessment and treatment of esophageal cancer. Gastrointest Endosc 2013;77:328–34.

64. Bennett C, Moayyedi P, Corley DA, et al; BOB CAT Consortium. BOB CAT: A large–scale review and delphi consensus for ,anagement of Barrett’s esophagus with no dysplasia, indefinite for, or low–grade dysplasia. Am J Gastroenterol 2015;110:662–82; quiz 683.

65. Sikkema M, de Jonge PJ, Steyerberg EW, Kuipers EJ. Risk of esophageal adenocarcinoma and mortality in patients with Barrett’s esophagus: a systematic review and meta–analysis. Clin Gastroenterol Hepatol 2010;8:235–44; quiz e32.

66. Old O, Moayyedi P, Love S, et al; BOSS Trial Team. Barrett’s Oesophagus Surveillance versus endoscopy at need Study (BOSS): protocol and analysis plan for a multicentre randomized controlled trial. J Med Screen 2015;22:158–64.

67. Weston AP, Sharma P, Topalovski M, et al. Long–term follow–up of Barrett’s high–grade dysplasia. Am J Gastroenterol 2000;95:1888–93.

68. Paull A, Trier JS, Dalton MD, et al. The histologic spectrum of Barrett’s esophagus. N Engl J Med 1976;295:476–80.

69. Konda VJ, Ross AS, Ferguson MK, et al. Is the risk of concomitant invasive esophageal cancer in high–grade dysplasia in Barrett’s esophagus overestimated? Clin Gastroenterol Hepatol 2008;6:159–64.

70. Allison H, Banchs MA, Bonis PA, Guelrud M. Long–term remission of nondysplastic Barrett’s esophagus after multipolar electrocoagulation ablation: report of 139 patients with 10 years of follow–up. Gastrointest Endosc 2011;73:651–8.

71. Corley DA, Levin TR, Habel LA, Weiss NS, et al. Surveillance and survival in Barrett’s adenocarcinomas: a population–based study. Gastroenterology 2002;122:633–40.

72. Wong T, Tian J, Nagar AB. Barrett’s surveillance identifies patients with early esophageal adenocarcinoma. Am J Med 2010;123:462–7.

73. Fountoulakis A, Zafirellis KD, Dolan K, et al. Effect of surveillance of Barrett’s oesophagus on the clinical outcome of oesophageal cancer. Br J Surg 2004;91:997–1003.

74. Verbeek RE, Leenders M, Ten Kate FJ, et al. Surveillance of Barrett’s esophagus and mortality from esophageal adenocarcinoma: a population–based cohort study. Am J Gastroenterol 2014;109:1215–22.

75. Kastelein F, van Olphen SH, Steyerberg EW, et al. Impact of surveillance for Barrett’s oesophagus on tumour stage and survival of patients with neoplastic progression. Gut 2016;65:548–54.

76. Phoa KN, van Vilsteren FG, Weusten BL, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low–grade dysplasia: a randomized clinical trial. JAMA 2014;311: 1209–17.

77. Wang WL, Chang IW, Chen CC, et al. Radiofrequency ablation versus endoscopic submucosal dissection in treating large early esophageal squamous cell neoplasia. Medicine (Baltimore) 2015;94:e2240.

78. Lim CH, Treanor D, Dixon MF, Axon AT. Low–grade dysplasia in Barrett’s esophagus has a high risk of progression. Endoscopy 2007;39:581–7.

79. Shaheen NJ, Inadomi JM, Overholt BF, Sharma P. What is the best management strategy for high grade dysplasia in Barrett’s oesophagus? A cost effectiveness analysis. Gut 2004;53:1736–44.

80. Vij R, Triadafilopoulos G, Owens DK, et al. Cost–effectiveness of photodynamic therapy for high–grade dysplasia in Barrett’s esophagus. Gastrointest Endosc 2004;60:739–56.

81. van den Boogert J, v an Hillegersberg R, Siersema PD, et al. Endoscopic ablation therapy for Barrett’s esophagus with high–grade dysplasia: a review. Am J Gastroenterol 1999;94:1153–60.

82. Sampliner RE. Endoscopic ablative therapy for Barrett’s esophagus: current status. Gastrointest Endosc 2004;59:66–9.

83. Sharma VK, Wang KK, Overholt BF, et al. Balloon–based, circumferential, endoscopic radiofrequency ablation of Barrett’s esophagus: 1–year follow–up of 100 patients. Gastrointest Endosc 2007;65:185–95.

84. Hanlon CR. Textbook of surgery: The biological basis of modern surgical practice, 14th edition. Ann Surg 1992;216:94.

85. Bright T, Watson DI, Tam W, et al. Randomized trial of argon plasma coagulation versus endoscopic surveillance for barrett esophagus after antireflux surgery: late results. Ann Surg 2007;246:1016–20.

86. Chadwick G, Groene O, Markar SR, et al. Systematic review comparing radiofrequency ablation and complete endoscopic resection in treating dysplastic Barrett’s esophagus: a critical assessment of histologic outcomes and adverse events. Gastrointest Endosc 2014;79:718–31.e3.

87. Gondrie JJ, Pouw RE, Sondermeijer CM, et al. Effective treatment of early Barrett’s neoplasia with stepwise circumferential and focal ablation using the HALO system. Endoscopy 2008;40:370–9.

88. Pouw RE, Wirths K, Eisendrath P, et al. Efficacy of radiofrequency ablation combined with endoscopic resection for barrett’s esophagus with early neoplasia. Clin Gastroenterol Hepatol 2010;8:23–9.

89. Kim HP, Bulsiewicz WJ, Cotton CC, et al. Focal endoscopic mucosal resection before radiofrequency ablation is equally effective and safe compared with radiofrequency ablation alone for the eradication of Barrett’s esophagus with advanced neoplasia. Gastrointest Endosc 2012;76:733–9.

90. Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic ablation of Barrett’s esophagus: a multicenter study with 2.5–year follow–up. Gastrointest Endosc 2008;68:867–76.

91. Sharma VK, Jae Kim H, Das A, et al. Circumferential and focal ablation of Barrett’s esophagus containing dysplasia. Am J Gastroenterol 2009;104:310–7.

92. Ganz RA, Overholt BF, Sharma VK, et al. Circumferential ablation of Barrett’s esophagus that contains high–grade dysplasia: a U.S. multicenter registry. Gastrointest Endosc 2008;68:35–40.

93. Gupta M, Iyer PG, Lutzke L, et al. Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett’s esophagus: results from a US Multicenter Consortium. Gastroenterology 2013;145:79–86.e1.

94. Lyday WD, Corbett FS, Kuperman DA, et al. Radiofrequency ablation of Barrett’s esophagus: outcomes of 429 patients from a multicenter community practice registry. Endoscopy 2010;42:272–8.

95. Pasricha S, Bulsiewicz WJ, Hathorn KE, et al. Durability and predictors of successful radiofrequency ablation for Barrett’s esophagus. Clin Gastroenterol Hepatol 2014;12:1840–7.e1.

96. Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic radiofrequency ablation for Barrett’s esophagus: 5–year outcomes from a prospective multicenter trial. Endoscopy 2010;42:781–9.

97. Weston AP, Sharma P, Banerjee S, et al. Visible endoscopic and histologic changes in the cardia, before and after complete Barrett’s esophagus ablation. Gastrointest Endosc 2005;61:515–21.

98. Beaumont H, Gondrie JJ, McMahon BP, et al. Stepwise radiofrequency ablation of Barrett’s esophagus preserves esophageal inner diameter, compliance, and motility. Endoscopy 2009;41:2–8.

99. Orman ES, Li N, Shaheen NJ.Efficacy and durability of radiofrequency ablation for Barrett’s Esophagus: systematic review and meta–analysis. Clin Gastroenterol Hepatol 2013;11:1245–55.

100. Krishnan K, Pandolfino JE, Kahrilas PJ, et al. Increased risk for persistent intestinal metaplasia in patients with Barrett’s esophagus and uncontrolled reflux exposure before radiofrequency ablation. Gastroenterology 2012;143:576–81.

101. Akiyama J, Marcus SN, Triadafilopoulos G. Effective intra–esophageal acid control is associated with improved radiofrequency ablation outcomes in Barrett’s esophagus. Dig Dis Sci 2012;57:2625–32.

102. Small AJ, Sutherland SE, Hightower JS, et al. Comparative risk of recurrence of dysplasia and carcinoma after endoluminal eradication therapy of high–grade dysplasia versus intramucosal carcinoma in Barrett’s esophagus. Gastrointest Endosc 2015;81:1158–66.e1–4.

103. Shaheen NJ, Greenwald BD, Peery AF, et al. Safety and efficacy of endoscopic spray cryotherapy for Barrett’s esophagus with high–grade dysplasia. Gastrointest Endosc 2010;71:680–5.

104. Shaheen NJ, Peery AF, Hawes RH, et al. Quality of life following radiofrequency ablation of dysplastic Barrett’s esophagus. Endoscopy 2010;42:790–9.

105. Bedi AO, Kwon RS, Rubenstein JH, et al. A survey of expert follow–up practices after successful endoscopic eradication therapy for Barrett’s esophagus with high–grade dysplasia and intramucosal adenocarcinoma. Gastrointest Endosc 2013;78:696–701.

106. Sampliner RE, Camargo E, Prasad AR. Prasad, Association of ablation of Barrett’s esophagus with high grade dysplasia and adenocarcinoma of the gastric cardia. Dis Esophagus 2006;19:277–9.

107. Overholt BF, Panjehpour M, Halberg DL. Photodynamic therapy for Barrett’s esophagus with dysplasia and/or early stage carcinoma: long–term results. Gastrointest Endosc 2003;58:183–8.

108. Gosain S, Mercer K, Twaddell WS, et al. Liquid nitrogen spray cryotherapy in Barrett’s esophagus with high–grade dysplasia: long–term results. Gastrointest Endosc 2013;78:260–5.

109. Canto MI, Shin EJ, Khashab MA, et al. Safety and efficacy of carbon dioxide cryotherapy for treatment of neoplastic Barrett’s esophagus. Endoscopy 2015;47:582–91.

110. Van Laethem JL, Peny MO, Salmon I, et al. Intramucosal adenocarcinoma arising under squamous re–epithelialisation of Barrett’s oesophagus. Gut 2000;46:574–7.

111. Pech O, May A, Gossner L, et al. Management of pre–malignant and malignant lesions by endoscopic resection. Best Pract Res Clin Gastroenterol 2004;18:61–76.

112. Soetikno RM, Gotoda T, Nakanishi Y, Soehendra N. Endoscopic mucosal resection. Gastrointest Endosc 2003;57:567–79.

113. Ell C, May A, Gossner L, et al. Endoscopic mucosal resection of early cancer and high–grade dysplasia in Barrett’s esophagus. Gastroenterology 2000;118:670–7.

114. Pech O, Behrens A, May A, et al. Long–term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high–grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett’s oesophagus. Gut 2008;57:1200–6.

115. Vieth M, Ell C, Gossner L, et al. Histological analysis of endoscopic resection specimens from 326 patients with Barrett’s esophagus and early neoplasia. Endoscopy 2004;36:776–81.

116. Buskens CJ, Westerterp M, Lagarde SM, et al. Prediction of appropriateness of local endoscopic treatment for high–grade dysplasia and early adenocarcinoma by EUS and histopathologic features. Gastrointest Endosc 2004;60:703–10.

117. Nijhawan PK, Wang KK. Endoscopic mucosal resection for lesions with endoscopic features suggestive of malignancy and high–grade dysplasia within Barrett’s esophagus. Gastrointest Endosc 2000;52:328–32.

118. Esaki M, Matsumoto T, Hirakawa K, et al. Risk factors for local recurrence of superficial esophageal cancer after treatment by endoscopic mucosal resection. Endoscopy 2007;39:41–5.

119. Ell C, May A, Pech O, et al. Curative endoscopic resection of early esophageal adenocarcinomas (Barrett’s cancer). Gastrointest Endosc 2007;65:3–10.

120. Chennat J, Konda VJ, Ross AS, et al. Complete Barrett’s eradication endoscopic mucosal resection: an effective treatment modality for high–grade dysplasia and intramucosal carcinoma––an American single–center experience. Am J Gastroenterol 2009;104:2684–92.

121. Pech O, Bollschweiler E, Manner H, et al. Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett’s esophagus at two high–volume centers. Ann Surg 2011;254:67–72.

122. Wu J, Pan YM, Wang TT, et al. Endotherapy versus surgery for early neoplasia in Barrett’s esophagus: a meta–analysis. Gastrointest Endosc 2014;79:233–241.e2.

123. Pech O, May A, Manner H, et al. Long–term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. Gastroenterology 2014;146:652–660.e1.

124. Prasad GA, Wu TT, Wigle DA, et al. Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett’s esophagus. Gastroenterology 2009;137:815–23.

125. May A, Gossner L, Pech O, et al. Local endoscopic therapy for intraepithelial high–grade neoplasia and early adenocarcinoma in Barrett’s oesophagus: acute–phase and intermediate results of a new treatment approach. Eur J Gastroenterol Hepatol 2002;14(10):1085–91.

126. Gerke H, Siddiqui J, Nasr I, et al. Efficacy and safety of EMR to completely remove Barrett’s esophagus: experience in 41 patients. Gastrointest Endosc 2011;74:761–71.

127. Lewis JJ, Rubenstein JH, Singal AG, et al. Factors associated with esophageal stricture formation after endoscopic mucosal resection for neoplastic Barrett’s esophagus. Gastrointest Endosc 2011;74:753–60.

128. Choi IJ, Kim CG, Chang HJ, et al. The learning curve for EMR with circumferential mucosal incision in treating intramucosal gastric neoplasm. Gastrointest Endosc 2005;62:860–5.

129. Deprez PH, Bergman JJ, Meisner S, et al. Current practice with endoscopic submucosal dissection in Europe: position statement from a panel of experts. Endoscopy 2010;42:853–8.

130. van Lanschot JJ, Hulscher JB, Buskens CJ, et al. Hospital volume and hospital mortality for esophagectomy. Cancer 2001;91:1574–8.

131. Karl RC, Schreiber R, Boulware D, et al. Factors affecting morbidity, mortality, and survival in patients undergoing Ivor Lewis esophagogastrectomy. Ann Surg 2000;231:635–43.

132. Young MM, Deschamps C, Trastek VF, et al. Esophageal reconstruction for benign disease: early morbidity, mortality, and functional results. Ann Thorac Surg 2000;70:1651–5.

133. Dunbar KB, Spechler SJ. The risk of lymph–node metastases in patients with high–grade dysplasia or intramucosal carcinoma in Barrett’s esophagus: a systematic review. Am J Gastroenterol 2012;107:850–62; quiz 863.

134. Morales CP, Souza RF, Spechler SJ. Hallmarks of cancer progression in Barrett’s oesophagus. Lancet 2002;360:1587–9.

135. Omer ZB, Ananthakrishnan AN, Nattinger KJ, et al. Aspirin protects against Barrett’s esophagus in a multivariate logistic regression analysis. Clin Gastroenterol Hepatol 2012;10:722–7.

136. Abnet CC, Freedman ND, Kamangar F, et al. Non–steroidal anti–inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta–analysis. Br J Cancer 2009;100:551–7.

137. Kastelein F, Spaander MC, Biermann K, et al. Nonsteroidal anti–inflammatory drugs and statins have chemopreventative effects in patients with Barrett’s esophagus. Gastroenterology 2011;141:2000–8; quiz e13–4.

138. Zhang S, Zhang XQ, Ding XW, et al. Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett’s esophagus: a meta–analysis. Br J Cancer 2014;110: 2378–88.

The long-term benefits of endoscopic intervention versus surgical intervention are not well established. Esophagectomy is no longer a preferred method of treatment due to high morbidity and mortality associated with the procedure when compared to endoscopic interventions. However, it is still a preferred choice amongst a select group of patients unwilling to follow-up. A cost-effective analysis found that endoscopic ablation provided the longest quality adjusted life expectancy for Barrett’s esophagus with HGD [79,80].

Endoscopic Therapy in Barrett’s Esophagus

Endoscopic Ablative Therapies

With the advancement of endoscopic intervention, we now have multiple tools to ablate abnormal epithelium in Barrett’s esophagus. Examples of ablation techniques include thermal, photochemical, and mechanical techniques [81,82]. RFA is the treatment of choice for ablation [83]. However, non-contact ablative therapy, such as cryoablation, may be prefered if topography of the esophagus doesn’t allow contact ablation.

Radiofrequency Ablation (Figure 2). RFA is a procedure in which heat is generated from medium frequency alternating current and leads to thermal injury [84]. In Barrett’s esophagus, RFA uses radiofrequency energy delivered by a balloon that has a series of closely spaced electrodes in a

circumferential pattern to ablate the Barrett’s mucosa by delivering thermal destructive energy with limited depth [83,85]. The other method to deliver the energy is an over the scope catheter. RFA has been proven by multiple studies to be safe and effective in eliminating dysplasia at the histological level with an acceptable safety profile. Those studies also demonstrated that RFA reduced the risk of malignant transformation [83,86]. In a meta-analysis of 20 studies, treatment of Barrett’s esophagus with RFA resulted in complete eradication of dysplasia in 91% of patients [99].

Most patients will require multiple sessions of RFA to achieve eradication. It is very rarely a one-time procedure. In a meta-analysis of 18 studies including 3082 patients, the most common adverse effects of RFA were stricture in 5% [76,98], bleeding in 1%, and pain in 3% of patients [99].

It is crucial for successful RFA to continue medical treatment for acid suppression, in order to allow healthy regeneration of the squamous cell lining. It is suggested to use PPI twice a day with sucralfate and ranitidine after the intervention [100,101]. Adhering to a liquid diet for 24 hours is needed, followed by a soft diet to allow faster regeneration of the epithelium.

The caveat with RFA is that new evidence shows a higher rate of recurrence than previously thought. In one study of 246 patients, recurrence of dysplasia occurred in 25% of patients at 48 months after eradication in 80% of the patients, and metaplasia occurred in 50% at 60 months [102]. The other risk is buried Barrett’s, a condition occurring after incomplete ablation, in which squamous cell epithelium covers patches of incompletely destroyed intestinal lining, leading to possible progression of the disease to adenocarcinoma under the surface [103].

It has been reported that patients who underwent RFA had remarkable improvement in quality of life even if RFA did not achieve eradication. Patients reported less depression, less stress and better quality of life [104].

Based on a survey of experts, follow-up at 3 months, 6 months, and then annually is recommended after ablation [1,105]. Biopsies should be taken distal to neosquamous epithelium and from suspicious areas [97,106].

Endoscopic Spray Cryotherapy. This technique involves application of liquid nitrogen or carbon dioxide gas by endoscope on the tissue to freeze it off. Although it has been shown to eliminate HGD in over 95% of the cases and all dysplasia in over 85% of the cases, it was effective in eradicating intestinal metaplasia in only 55% of patients [103,108,109]. Thus, RFA as ablation therapy is still superior to cryotherapy and is still the first-line treatment for dysplastic Barrett’s esophagus. In comparison to cryotherapy, RFA efficacy has been studied extensively with well documented outcomes. However, there is a role for cryotherapy over RFA in certain clinical situations (such as severe chest pain from RFA or lack of efficacy in eradicating intestinal metaplasia or dysplasia by RFA).

Similar to RFA, on occasions of partial ablation, the remaining metaplastic tissue may get buried beneath a layer of squamous epithelium and can possibly progress to adenocarcinoma [110].

Photodynamic Therapy (PDT). This technique works by producing cytotoxicity at the cellular level by exposure to light at a specific wavelength in the presence of a chemical agent known as photosensitize [107]. Although superior to omeprazole, PDT has a significant rate of complications, mainly stricture, and a high occurrence of esophageal cancer during follow-up. For this reason, it is less favorable compared to RFA [107] and mentioned here as a historical therapy.